{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:37:50Z","timestamp":1787009870935,"version":"build-2736575974"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Interstitial lung disease (ILD) associates with disease burden and reduced life expectancy in systemic sclerosis (SSc). As ILD afflicts around 50% of SSc patients and is often present from early on, there is rationale for early and universal ILD screening. With the approval of the first SSc-ILD therapy last year, there is an increasing need for ILD classifications to assign the right treatment to the right patient. Here, we discuss recent advances on screening, detection, and classification of SSc-ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Although prospective datasets from a nationwide population-based SSc cohort confirm insufficient sensitivity of pulmonary function tests (PFTs) for ILD screening, they provide strong support for lung high resolution computed tomography (HRCT) as the primary tool to detect ILD. Lung ultrasound shows promise as an additional screening tool. Interpreting statements from a new European consensus on SSc-ILD management, we propose an urgent need for integrated SSc classification, grading ILD severity at time of diagnosis and evaluate risk for ILD progression. We discuss advances on potential parameters for such classification, including PFTs, quantitative HRCT analyses, patient-reported outcome measures, functional exercise capacity tests, and soluble biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Early screening to diagnose ILD is feasible. With new therapies at hand, there is a need for integrated ILD classification including severity grading and risk for progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000741","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T17:08:09Z","timestamp":1599239289000},"page":"497-504","source":"Crossref","is-referenced-by-count":25,"title":["Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis"],"prefix":"10.1097","volume":"32","author":[{"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital (OUH)"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind","family":"Molberg","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Oslo University Hospital (OUH)"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semarthrit.2016.02.005","article-title":"Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey","volume":"46","author":"Frantz","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41584-018-0062-0","article-title":"Major lung complications of systemic sclerosis","volume":"14","author":"Denton","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","article-title":"Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort","volume":"200","author":"Hoffmann-Vold","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"R7-20230829","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaa026","article-title":"Multidimensional tracking of phenotypes and organ involvement in a complete nationwide systemic sclerosis cohort","author":"Fretheim","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"e0163894","DOI":"10.1371\/journal.pone.0163894","article-title":"Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study","volume":"11","author":"Jaeger","year":"2016","journal-title":"PLoS One"},{"key":"R9-20230829","first-page":"239719831988954","article-title":"Natural history of systemic sclerosis\u2013related interstitial lung disease: how to identify a progressive fibrosing phenotype","author":"Volkmann","year":"2019","journal-title":"J Scleroderma Relat Disord"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S2213-2600(17)30387-9","article-title":"Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study","volume":"5","author":"Allen","year":"2017","journal-title":"Lancet Respir Med"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03007995.2019.1647040","article-title":"Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management","volume":"35","author":"Wijsenbeek","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"1801939","DOI":"10.1183\/13993003.01939-2018","article-title":"Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name?","volume":"53","author":"Wells","year":"2019","journal-title":"Eur Respir J"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S2213-2600(17)30383-1","article-title":"Palliative care in interstitial lung disease: living well","volume":"5","author":"Kreuter","year":"2017","journal-title":"Lancet Respir Med"},{"key":"R14-20230829","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0076-2018","article-title":"Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur Respir Rev"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1513\/AnnalsATS.201806-362OC","article-title":"Does systemic sclerosis-associated interstitial lung disease burn out? Specific phenotypes of disease progression","volume":"15","author":"Guler","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/1744666X.2020.1668269","article-title":"Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease","volume":"15","author":"Distler","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","article-title":"The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements","volume":"2","author":"Hoffmann-Vold","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"180073","DOI":"10.1183\/16000617.0073-2018","article-title":"Role of imaging in progressive-fibrosing interstitial lung diseases","volume":"27","author":"Walsh","year":"2018","journal-title":"Eur Respir Rev"},{"key":"R22-20230829","first-page":"593","article-title":"Diagnostic accuracy of x-ray chest in interstitial lung disease as conformed by Hugh resolution computed tomography (HRCT) chest","volume":"67","author":"Afzal","year":"2017","journal-title":"Pak Armed Forces Med J"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1183\/09031936.00001612","article-title":"Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis?","volume":"40","author":"Cottin","year":"2012","journal-title":"Eur Respir J"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1002\/art.39405","article-title":"Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease","volume":"67","author":"Suliman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/BOR.0000000000000323","article-title":"Interstitial lung disease in systemic sclerosis: progress in screening and early diagnosis","volume":"28","author":"Molberg","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1164\/rccm.201903-0563CI","article-title":"Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease","volume":"201","author":"Khanna","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"R27-20230829","first-page":"239719831989485","article-title":"Circulating biomarkers of systemic sclerosis: interstitial lung disease","author":"Hoffmann-Vold","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3899\/jrheum.180940","article-title":"Ultrasound in the assessment of interstitial lung disease in systemic sclerosis: a systematic literature review by the OMERACT Ultrasound Group","volume":"47","author":"Gutierrez","year":"2019","journal-title":"J Rheumatol"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1148\/radiol.2019182099","article-title":"Use of elastic registration in pulmonary MRI for the assessment of pulmonary fibrosis in patients with systemic sclerosis","volume":"291","author":"Chassagnon","year":"2019","journal-title":"Radiology"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/ard.2008.091710","article-title":"Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study","volume":"68","author":"Vonk","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/BOR.0000000000000592","article-title":"Management of systemic sclerosis-associated interstitial lung disease","volume":"31","author":"Roofeh","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3899\/jrheum.141182","article-title":"Connective tissue disease-associated interstitial lung diseases (CTD-ILD): report from OMERACT CTD-ILD working group","volume":"42","author":"Khanna","year":"2015","journal-title":"J Rheumatol"},{"key":"R36-20230829","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-020-05105-4","article-title":"Progressive lung fibrosis and mortality can occur in early systemic sclerosis patients without pulmonary abnormalities at baseline assessment","author":"Vanaken","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/RHU.0000000000000860","article-title":"Lung ultrasound as a screening method for interstitial lung disease in patients with systemic sclerosis","volume":"25","author":"Hassan","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College Of Rheumatology\/European League against Rheumatism Collaborative Initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R39-20230829","article-title":"Development and assessment of a novel lung ultrasound interpretation criteria for the detection of interstitial lung disease in systemic sclerosis","author":"Fairchild","year":"2020","journal-title":"Arthritis Care Res"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"Bouros","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2169\/internalmedicine.48.1714","article-title":"Nonspecific interstitial pneumonia associated with collagen vascular disease: analysis of CT features to distinguish the various types","volume":"48","author":"Daimon","year":"2009","journal-title":"Intern Med"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1183\/09031936.98.12051010","article-title":"Idiopathic nonspecific interstitial pneumonia\/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP","volume":"12","author":"Nagai","year":"1998","journal-title":"Eur Respir J"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial lung disease associated with systemic sclerosis (SSc-ILD)","volume":"20","author":"Cottin","year":"2019","journal-title":"Respir Res"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/rheumatology\/kes289","article-title":"Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease","volume":"52","author":"Moore","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/09041950.005s1693","article-title":"Report working party standardization of lung function tests, European community for steel and coal: official statement of the European Respiratory Society","volume":"16","author":"Quanjer","year":"1993","journal-title":"Eur Respir J Suppl"},{"key":"R48-20230829","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","article-title":"Severe organ involvement in systemic sclerosis with diffusion scleroderma","volume":"43","author":"Steen","year":"2000","journal-title":"Arthritis Rheumat"},{"key":"R49-20230829","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/rheumatology\/kev121","article-title":"A decision model for the watch-and-wait strategy in systemic sclerosis-associated interstitial lung disease","volume":"54","author":"Kwon","year":"2015","journal-title":"Rheumatology"},{"key":"R50-20230829","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.chest.2016.11.052","article-title":"Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease","volume":"151","author":"Tashkin","year":"2017","journal-title":"Chest"},{"key":"R51-20230829","doi-asserted-by":"crossref","first-page":"e0181692","DOI":"10.1371\/journal.pone.0181692","article-title":"Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease","volume":"12","author":"Le Gouellec","year":"2017","journal-title":"PLoS One"},{"key":"R52-20230829","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"R53-20230829","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"R54-20230829","doi-asserted-by":"crossref","first-page":"1902026","DOI":"10.1183\/13993003.02026-2019","article-title":"Predictors of progression in systemic sclerosis patients with interstitial lung disease","volume":"55","author":"Distler","year":"2020","journal-title":"Eur Respir J"},{"key":"R55-20230829","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrrheum.2009.238","article-title":"Autoantibodies as predictive tools in systemic sclerosis","volume":"6","author":"Nihtyanova","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"R56-20230829","doi-asserted-by":"crossref","first-page":"e000826","DOI":"10.1136\/rmdopen-2018-000826","article-title":"Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features","volume":"5","author":"Hoffmann-Vold","year":"2019","journal-title":"RMD Open"},{"key":"R58-20230829","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"R59-20230829","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/annrheumdis-2018-213455","article-title":"Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort","volume":"78","author":"Wu","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R60-20230829","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3899\/jrheum.170055","article-title":"Scleroderma lung involvement, autoantibodies, and outcome prediction: the confounding effect of time","volume":"44","author":"Nihtyanova","year":"2017","journal-title":"J Rheumatol"},{"key":"R61-20230829","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R62-20230829","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1002\/art.30467","article-title":"Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R63-20230829","first-page":"30068","article-title":"Evolution of high-resolution CT-scan in systemic sclerosis-associated interstitial lung disease: description and prognosis factors","volume":"S0049-0172","author":"Forestier","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R64-20230829","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/art.39166","article-title":"Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis","volume":"67","author":"Hoffmann-Vold","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R65-20230829","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s10067-020-04938-3","article-title":"Assessment of interstitial lung disease in systemic sclerosis using the quantitative CT algorithm CALIPER","volume":"39","author":"Ferrazza","year":"2020","journal-title":"Clin Rheumatol"},{"key":"R66-20230829","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1136\/annrheumdis-2018-213201","article-title":"Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model","volume":"77","author":"Wu","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R67-20230829","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/art.40815","article-title":"Performance of candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease","volume":"71","author":"Elhai","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R68-20230829","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/art.40171","article-title":"CCL-2 in the circulation predicts long-term progression of interstitial lung disease in early systemic sclerosis patients: data from two independent cohorts","volume":"69","author":"Wu","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R69-20230829","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jbspin.2020.02.003","article-title":"Squamous cell carcinoma antigen-IgM (SCCA-IgM) is associated with interstitial lung disease in systemic sclerosis","volume":"87","author":"Zanatta","year":"2020","journal-title":"Joint Bone Spine"},{"key":"R70-20230829","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaa195","article-title":"Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma","author":"Yaseen","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R71-20230829","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"R72-20230829","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"(Suppl 10)","key":"R73-20230829","article-title":"Efficacy and safety of tocilizumab for the treatment of systemic sclerosis: results from a phase 3 randomized controlled trial","volume":"70","author":"Khanna","year":"2018","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T03:15:19Z","timestamp":1693278919000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":72,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000741","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]}}}